DrugChatter adds coverage of recently approved drugs
A common challenge faced pharmaceutical industry analysts, pharmacists, and other healthcare professionals is obtaining objective information on recently approved drugs. Often the only source of information in the first months after a drug’s launch is from sales representatives who may not have access to raw clinical data.
DrugChatter fills this gap by tapping into the DrugPatentWatch database and mining social media to bring you public opinions on recently-approved drugs . DrugChatter also provides details on the most discussed drugs, and can supplement focus groups with its profiles of pharmaceutical drug ads.
I invite you to take a look at this new site in development, and let me know what you think.